Skip to main content
S 148 118th Congress Senate Health Administrative remedies Business ethics Civil actions and liability Competition and antitrust Department of Health and Human Services Drug safety, medical device, and laboratory regulation Food and Drug Administration (FDA) Licensing and registrations Prescription drugs Public participation and lobbying

Stop STALLING Act

Introduced: January 30, 2023 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Jan 30, 2023
Read twice and referred to the Committee on the Judiciary.
Jan 30, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop STALLING Act

This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.

The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit shall be subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.

What's happening now March 1, 2023

Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.

 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 7

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

See all 7 filings →
 Cosponsors 7
All 7 Democratic 5 Republican 2
D
Welch, Peter
Vermont · Feb 9, 2023
 D
Ossoff, Jon
Georgia · Feb 1, 2023
 D
Blumenthal, Richard
Connecticut · Jan 30, 2023
 D
Booker, Cory A.
New Jersey · Jan 30, 2023
 R
Cruz, Ted
Texas · Jan 30, 2023
 D
Durbin, Richard J.
Illinois · Jan 30, 2023
 R
Grassley, Chuck
Iowa · Jan 30, 2023
Cite this page click to expand
APA
U.S. Congress. (2026). S. 148: Stop STALLING Act. 118th Congress. Open America. https://openamerica.io/bill/118-S-148/
MLA
"S. 148: Stop STALLING Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-148/.
Bluebook (legal)
S. 148, 118th Cong. (2026), https://openamerica.io/bill/118-S-148/.
Markdown link
[S. 148: Stop STALLING Act](https://openamerica.io/bill/118-S-148/)
Report a problem